跳至主要内容
临床试验/NCT00031135
NCT00031135终止2 期

Prevention of TPN-Associated Hepatic Steatosis: A Placebo Controlled Trial

Northwestern University2 个研究点 分布在 1 个国家目标入组 48 人开始时间: 2001年9月1日最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
终止
入组人数
48
试验地点
2

研究概览

简要总结

This is a study to determine whether choline, when added to total parenteral nutrition (TPN), can help prevent the development of hepatic steatosis, a liver disease, in patients on TPN.

详细描述

Choline deficiency-induced hepatic steatosis occurs in patients that require long-term TPN and may progress to significant hepatic disease and death. Initial studies indicate choline-supplemented TPN may reverse TPN-associated hepatic steatosis.

Choline chloride or placebo will be added to each patient's TPN for 16 weeks by the hospital or pharmacy providing their usual TPN. Patients will receive their TPN in the hospital until they are medically stable for discharge. If patients are discharged before study completion, the pharmacy will deliver the TPN supply to them. Evaluation of hepatic steatosis is done by CT scans and blood analyses. Blood will be drawn on a biweekly basis during the first 4 weeks and at Week 8, 12, 16 or withdrawal. CT scans will be done at Week 4, 8, 16, or withdrawal.

Completion date provided represents the completion date of the grant per OOPD records

研究设计

研究类型
Interventional
分配方式
Randomized
主要目的
Prevention
盲法
Double

入排标准

年龄范围
21 Years 至 74 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Underlying pathology may include, but is not limited to: short bowel syndrome, chronic pancreatitis, pancreatic pseudocysts, pseudo-obstruction, enterocutaneous fistula, entero-enteric fistula, or malabsorption syndrome.
  • Requirement for TPN to supply greater than 85 percent of nutritional needs for at least 16 weeks.

排除标准

  • Not receiving lipid emulsion with TPN regimen
  • Albumin less than 2.5 g/L
  • Renal failure requiring hemo- or peritoneal dialysis
  • Hepatic failure (PT greater than 2 times control)
  • Hepatitis C
  • Concurrent hospitalization for organ transplantation or rejection treatment
  • Concurrent cholinergic medication
  • Positive pregnancy test
  • Refusal to use an acceptable method of birth control
  • Ethanol abuse
  • More than 40 kcal/kg/day ideal body weight
  • Obesity with ensuing weight loss
  • Use of IV tetracycline, valproic acid, corticosteroids, methotrexate, or amiodarone

研究者

申办方类型
Other

研究点 (2)

Loading locations...

相似试验